Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy
Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure. Fortunately, the disease now has an approved therapy, with many others under development. Assessment of prognosis in ATTR-CM is critical to inform patients about the disease course and...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-12-01
|
| Series: | JACC. CardioOncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666087319300912 |
| _version_ | 1811294288726720512 |
|---|---|
| author | Kent Y. Feng, MD Rahul S. Loungani, MD Vishal N. Rao, MD, MPH Chetan B. Patel, MD Michel G. Khouri, MD G. Michael Felker, MD, MHS Adam D. DeVore, MD, MHS |
| author_facet | Kent Y. Feng, MD Rahul S. Loungani, MD Vishal N. Rao, MD, MPH Chetan B. Patel, MD Michel G. Khouri, MD G. Michael Felker, MD, MHS Adam D. DeVore, MD, MHS |
| author_sort | Kent Y. Feng, MD |
| collection | DOAJ |
| description | Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure. Fortunately, the disease now has an approved therapy, with many others under development. Assessment of prognosis in ATTR-CM is critical to inform patients about the disease course and guide clinical decisions. This review discusses the evidence behind clinical, biomarker, and imaging findings that inform prognosis in patients with ATTR-CM and can assist providers in the shared decision-making process during management of this disease. |
| first_indexed | 2024-04-13T05:15:15Z |
| format | Article |
| id | doaj.art-01dc914b21a34c549e940ecc676cd2b8 |
| institution | Directory Open Access Journal |
| issn | 2666-0873 |
| language | English |
| last_indexed | 2024-04-13T05:15:15Z |
| publishDate | 2019-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JACC. CardioOncology |
| spelling | doaj.art-01dc914b21a34c549e940ecc676cd2b82022-12-22T03:00:55ZengElsevierJACC. CardioOncology2666-08732019-12-0112273279Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid CardiomyopathyKent Y. Feng, MD0Rahul S. Loungani, MD1Vishal N. Rao, MD, MPH2Chetan B. Patel, MD3Michel G. Khouri, MD4G. Michael Felker, MD, MHS5Adam D. DeVore, MD, MHS6Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CaliforniaDivision of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North CarolinaDivision of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North CarolinaDivision of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North CarolinaDivision of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North CarolinaDivision of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North CarolinaDivision of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina; Address for correspondence: Dr. Adam D. DeVore, Duke Clinical Research Institute, 200 Morris Street, #6318, Durham, North Carolina 27701.Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure. Fortunately, the disease now has an approved therapy, with many others under development. Assessment of prognosis in ATTR-CM is critical to inform patients about the disease course and guide clinical decisions. This review discusses the evidence behind clinical, biomarker, and imaging findings that inform prognosis in patients with ATTR-CM and can assist providers in the shared decision-making process during management of this disease.http://www.sciencedirect.com/science/article/pii/S2666087319300912amyloidosisbiomarkerscardiac magnetic resonancecardiomyopathyechocardiographynuclear imaging |
| spellingShingle | Kent Y. Feng, MD Rahul S. Loungani, MD Vishal N. Rao, MD, MPH Chetan B. Patel, MD Michel G. Khouri, MD G. Michael Felker, MD, MHS Adam D. DeVore, MD, MHS Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy JACC. CardioOncology amyloidosis biomarkers cardiac magnetic resonance cardiomyopathy echocardiography nuclear imaging |
| title | Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy |
| title_full | Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy |
| title_fullStr | Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy |
| title_full_unstemmed | Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy |
| title_short | Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy |
| title_sort | best practices for prognostic evaluation of a patient with transthyretin amyloid cardiomyopathy |
| topic | amyloidosis biomarkers cardiac magnetic resonance cardiomyopathy echocardiography nuclear imaging |
| url | http://www.sciencedirect.com/science/article/pii/S2666087319300912 |
| work_keys_str_mv | AT kentyfengmd bestpracticesforprognosticevaluationofapatientwithtransthyretinamyloidcardiomyopathy AT rahulslounganimd bestpracticesforprognosticevaluationofapatientwithtransthyretinamyloidcardiomyopathy AT vishalnraomdmph bestpracticesforprognosticevaluationofapatientwithtransthyretinamyloidcardiomyopathy AT chetanbpatelmd bestpracticesforprognosticevaluationofapatientwithtransthyretinamyloidcardiomyopathy AT michelgkhourimd bestpracticesforprognosticevaluationofapatientwithtransthyretinamyloidcardiomyopathy AT gmichaelfelkermdmhs bestpracticesforprognosticevaluationofapatientwithtransthyretinamyloidcardiomyopathy AT adamddevoremdmhs bestpracticesforprognosticevaluationofapatientwithtransthyretinamyloidcardiomyopathy |